K Ramalingam¹*, P Karnan² and A Anbarasu³

¹Mediclone Biotech Research Centre, Chennai, Dr. Rai Memorial and Medical Centre (Cancer Treatment and Research), I.E.C Member, India
²Associate Professor, GRT College of Education, Tiruttani, Tiruallur, India
³PG Assistant in Biology, Government Higher Secondary School, Chithathur, Tiruvannamalai, India

*Corresponding Author: K Ramalingam, Mediclone Biotech Research Centre, Chennai, Dr. Rai Memorial and Medical Centre (Cancer Treatment and Research), I.E.C Member, India.

Received: January 17, 2023 Published: December 31, 2022

Abstract

In the event of the fortuitous emergence and outbreak of corona virus in 2019 and the great toll of human life in millions by COVID-19 next to Spanish flu syndrome in the world (1918), the probability of cancer incidence and its increase in human population may not be ruled out by the thinking that the corona virus outbreak since 2019 and its phenotype modifications into variants to date will not be a worldwide cancer burden in view of the WHOs (GENEVA) statement that 50 percent of world population are the would be sufferers of cancer disease in the near future due to multifarious factors. The above hypothesis may be considered as conceivable in view of the generalization that viruses are causative agents for malignant cancers. John B Leo., et al. [1].

References

1. John B Liao. “Viruses and Human Cancer”. Yale Journal of Biology and Medicine3-4 (2006): 115-122.
2. Pearson CAB., et al. “Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 Variants 501Y.V2”. Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine.
3. Xie X., et al. “SARS-CoV-2 spike E484K mutation reduces antibody neutralization”. The Lancet7 (2021): 283-284.
4. Garcia Beltran W., et al. “Multiple SARS-CoV-2 Variants escape neutralization”. Cell9 (2021): 2372-2383.
5. Orth G., et al. “Characterization of two types of human papilloma viruses in lesions of epidermo dysplasia verruciformis””. Proceedings of the National Academy of Sciences of the United States of America 75 (1978): 1537-1541.
6. COVID-19. SARS-CoV-2 Variant Classifications and Definitions, Centers for diseases control Prevention, USA (2022).
7. DeVita, Hellman, and Rosenberg's. Cancer: Principles and Practice of Oncology (Cancer Principles and Practice of Oncology) Twelfth Edition, Wolters Kluwer (2022).
8. Allison J Greaney., et al. “Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies”. Cell Host Microbe3 (2021): 463-476.e6.
9. Oscar Solis., et al. “The SARS-CoV-2 spike protein binds and modulates estrogen receptors”. BioRxiv (2022).
10. Montopoli M., et al. “Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)”. Annals of Oncology 31 (2020): 1040-1045.

Citation

Citation: K Ramalingam., et al. “Probability of SARS-CoV-2 Infections for Future Cancer Incidence in World Population - A Commentary". Acta Scientific Pharmacology 4.1 (2023): 32-34.

Copyright

Copyright: © 2022 K Ramalingam., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.